Research ArticleArticle
Open Access
Evidence-based Recommendations for the Management of Comorbidities in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Expert Opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative
Camille Roubille, Vincent Richer, Tara Starnino, Collette McCourt, Alexandra McFarlane, Patrick Fleming, Stephanie Siu, John Kraft, Charles Lynde, Janet Pope, Wayne Gulliver, Stephanie Keeling, Jan Dutz, Louis Bessette, Robert Bissonnette and Boulos Haraoui
The Journal of Rheumatology July 2015, jrheum.141112; DOI: https://doi.org/10.3899/jrheum.141112
Camille Roubille
From the University of Montreal Hospital Research Center (Centre de Recherche du CHUM), Notre-Dame Hospital; Department of Medicine, Dermatology Service, St-Luc Hospital; Sacré-Coeur Hospital of Montreal, University of Montreal; Innovaderm Research; Institut de Rhumatologie de Montréal, Montreal; Centre de Recherche du CHU de Québec, Department of Medicine, Laval University, Quebec City, Quebec; Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia; Division of Rheumatology, University of Alberta, Edmonton, Alberta; Division of Dermatology, University of Toronto, Toronto; Division of Rheumatology, Western University of Canada, London; Lynde Dermatology, Markham, Ontario; Faculty of Medicine, Memorial University of Newfoundland, St. John’s, Newfoundland, Canada. AbbVie sponsored a meeting on the management of comorbidities, held in Toronto, Ontario, Canada, on May 31 to June 1, 2013. This publication summarizes the results of the Canadian Dermatology-Rheumatology (DR) Co-morbidity Initiative systematic literature searches (MEDLINE, EMBASE, Cochrane Library, 2010–2012 American College of Rheumatology, European League Against Rheumatism, American Academy of Dermatology, European Academy of Dermatology and Venereology abstracts) and consensus-based recommendations from that meeting. AbbVie provided funding to Pinnacle Marketing and Education Inc. to manage the Canadian DR Co-morbidity Initiative that led to this paper. AbbVie paid consultancy fees to BH, JP, LB, SK, RB, WG, JD, CL, and JK for their participation in the Canadian DR Co-morbidity Initiative. AbbVie paid Leading Edge for editorial support. C. Roubille, MD, Rheumatology Research Fellow, University of Montreal Hospital Research Center (Centre de Recherche du CHUM), Notre-Dame Hospital; V. Richer, MD, Dermatology Resident, Department of Medicine, Dermatology Service, St-Luc Hospital; T. Starnino, MD, Rheumatology Resident, Sacré-Coeur Hospital of Montreal, University of Montreal; C. McCourt, MB, BCh, Clinical Fellow in Immunodermatology, Department of Dermatology and Skin Science, University of British Columbia; A. McFarlane, MD, Internal Medicine Resident, Division of Rheumatology, University of Alberta; P. Fleming, MD, Dermatology Resident, Division of Dermatology, University of Toronto; S. Siu, MD, Internal Medicine Resident, Division of Rheumatology, Western University of Canada; J. Kraft, MD, Dermatologist; C. Lynde, MD, Dermatologist, Lynde Dermatology; J. Pope, MD, Professor of Rheumatology, Division of Rheumatology, Western University of Canada; W. Gulliver, MD, Professor of Medicine, Faculty of Medicine, Memorial University of Newfoundland; S. Keeling, MD, Associate Professor of Rheumatology, Division of Rheumatology, University of Alberta; J. Dutz, MD, Professor of Dermatology, Department of Dermatology and Skin Science, University of British Columbia; L. Bessette, MD, Associate Professor of Medicine, Centre de Recherche du CHU de Québec, Department of Medicine, Laval University; R. Bissonnette, MD, Medical Director, Innovaderm Research; B. Haraoui, MD, Head of Clinical Research Unit, Institut de Rhumatologie de Montréal. Address correspondence to Dr. B. Haraoui, Institut de Rhumatologie de Montreal, 1551 Ontario St. East, Montreal, Quebec H2L 1S6, Canada. E-mail: boulos.haraoui@ssss.gouv.qc.ca. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication May 4, 2015.
Vincent Richer
From the University of Montreal Hospital Research Center (Centre de Recherche du CHUM), Notre-Dame Hospital; Department of Medicine, Dermatology Service, St-Luc Hospital; Sacré-Coeur Hospital of Montreal, University of Montreal; Innovaderm Research; Institut de Rhumatologie de Montréal, Montreal; Centre de Recherche du CHU de Québec, Department of Medicine, Laval University, Quebec City, Quebec; Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia; Division of Rheumatology, University of Alberta, Edmonton, Alberta; Division of Dermatology, University of Toronto, Toronto; Division of Rheumatology, Western University of Canada, London; Lynde Dermatology, Markham, Ontario; Faculty of Medicine, Memorial University of Newfoundland, St. John’s, Newfoundland, Canada. AbbVie sponsored a meeting on the management of comorbidities, held in Toronto, Ontario, Canada, on May 31 to June 1, 2013. This publication summarizes the results of the Canadian Dermatology-Rheumatology (DR) Co-morbidity Initiative systematic literature searches (MEDLINE, EMBASE, Cochrane Library, 2010–2012 American College of Rheumatology, European League Against Rheumatism, American Academy of Dermatology, European Academy of Dermatology and Venereology abstracts) and consensus-based recommendations from that meeting. AbbVie provided funding to Pinnacle Marketing and Education Inc. to manage the Canadian DR Co-morbidity Initiative that led to this paper. AbbVie paid consultancy fees to BH, JP, LB, SK, RB, WG, JD, CL, and JK for their participation in the Canadian DR Co-morbidity Initiative. AbbVie paid Leading Edge for editorial support. C. Roubille, MD, Rheumatology Research Fellow, University of Montreal Hospital Research Center (Centre de Recherche du CHUM), Notre-Dame Hospital; V. Richer, MD, Dermatology Resident, Department of Medicine, Dermatology Service, St-Luc Hospital; T. Starnino, MD, Rheumatology Resident, Sacré-Coeur Hospital of Montreal, University of Montreal; C. McCourt, MB, BCh, Clinical Fellow in Immunodermatology, Department of Dermatology and Skin Science, University of British Columbia; A. McFarlane, MD, Internal Medicine Resident, Division of Rheumatology, University of Alberta; P. Fleming, MD, Dermatology Resident, Division of Dermatology, University of Toronto; S. Siu, MD, Internal Medicine Resident, Division of Rheumatology, Western University of Canada; J. Kraft, MD, Dermatologist; C. Lynde, MD, Dermatologist, Lynde Dermatology; J. Pope, MD, Professor of Rheumatology, Division of Rheumatology, Western University of Canada; W. Gulliver, MD, Professor of Medicine, Faculty of Medicine, Memorial University of Newfoundland; S. Keeling, MD, Associate Professor of Rheumatology, Division of Rheumatology, University of Alberta; J. Dutz, MD, Professor of Dermatology, Department of Dermatology and Skin Science, University of British Columbia; L. Bessette, MD, Associate Professor of Medicine, Centre de Recherche du CHU de Québec, Department of Medicine, Laval University; R. Bissonnette, MD, Medical Director, Innovaderm Research; B. Haraoui, MD, Head of Clinical Research Unit, Institut de Rhumatologie de Montréal. Address correspondence to Dr. B. Haraoui, Institut de Rhumatologie de Montreal, 1551 Ontario St. East, Montreal, Quebec H2L 1S6, Canada. E-mail: boulos.haraoui@ssss.gouv.qc.ca. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication May 4, 2015.
Tara Starnino
From the University of Montreal Hospital Research Center (Centre de Recherche du CHUM), Notre-Dame Hospital; Department of Medicine, Dermatology Service, St-Luc Hospital; Sacré-Coeur Hospital of Montreal, University of Montreal; Innovaderm Research; Institut de Rhumatologie de Montréal, Montreal; Centre de Recherche du CHU de Québec, Department of Medicine, Laval University, Quebec City, Quebec; Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia; Division of Rheumatology, University of Alberta, Edmonton, Alberta; Division of Dermatology, University of Toronto, Toronto; Division of Rheumatology, Western University of Canada, London; Lynde Dermatology, Markham, Ontario; Faculty of Medicine, Memorial University of Newfoundland, St. John’s, Newfoundland, Canada. AbbVie sponsored a meeting on the management of comorbidities, held in Toronto, Ontario, Canada, on May 31 to June 1, 2013. This publication summarizes the results of the Canadian Dermatology-Rheumatology (DR) Co-morbidity Initiative systematic literature searches (MEDLINE, EMBASE, Cochrane Library, 2010–2012 American College of Rheumatology, European League Against Rheumatism, American Academy of Dermatology, European Academy of Dermatology and Venereology abstracts) and consensus-based recommendations from that meeting. AbbVie provided funding to Pinnacle Marketing and Education Inc. to manage the Canadian DR Co-morbidity Initiative that led to this paper. AbbVie paid consultancy fees to BH, JP, LB, SK, RB, WG, JD, CL, and JK for their participation in the Canadian DR Co-morbidity Initiative. AbbVie paid Leading Edge for editorial support. C. Roubille, MD, Rheumatology Research Fellow, University of Montreal Hospital Research Center (Centre de Recherche du CHUM), Notre-Dame Hospital; V. Richer, MD, Dermatology Resident, Department of Medicine, Dermatology Service, St-Luc Hospital; T. Starnino, MD, Rheumatology Resident, Sacré-Coeur Hospital of Montreal, University of Montreal; C. McCourt, MB, BCh, Clinical Fellow in Immunodermatology, Department of Dermatology and Skin Science, University of British Columbia; A. McFarlane, MD, Internal Medicine Resident, Division of Rheumatology, University of Alberta; P. Fleming, MD, Dermatology Resident, Division of Dermatology, University of Toronto; S. Siu, MD, Internal Medicine Resident, Division of Rheumatology, Western University of Canada; J. Kraft, MD, Dermatologist; C. Lynde, MD, Dermatologist, Lynde Dermatology; J. Pope, MD, Professor of Rheumatology, Division of Rheumatology, Western University of Canada; W. Gulliver, MD, Professor of Medicine, Faculty of Medicine, Memorial University of Newfoundland; S. Keeling, MD, Associate Professor of Rheumatology, Division of Rheumatology, University of Alberta; J. Dutz, MD, Professor of Dermatology, Department of Dermatology and Skin Science, University of British Columbia; L. Bessette, MD, Associate Professor of Medicine, Centre de Recherche du CHU de Québec, Department of Medicine, Laval University; R. Bissonnette, MD, Medical Director, Innovaderm Research; B. Haraoui, MD, Head of Clinical Research Unit, Institut de Rhumatologie de Montréal. Address correspondence to Dr. B. Haraoui, Institut de Rhumatologie de Montreal, 1551 Ontario St. East, Montreal, Quebec H2L 1S6, Canada. E-mail: boulos.haraoui@ssss.gouv.qc.ca. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication May 4, 2015.
Collette McCourt
From the University of Montreal Hospital Research Center (Centre de Recherche du CHUM), Notre-Dame Hospital; Department of Medicine, Dermatology Service, St-Luc Hospital; Sacré-Coeur Hospital of Montreal, University of Montreal; Innovaderm Research; Institut de Rhumatologie de Montréal, Montreal; Centre de Recherche du CHU de Québec, Department of Medicine, Laval University, Quebec City, Quebec; Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia; Division of Rheumatology, University of Alberta, Edmonton, Alberta; Division of Dermatology, University of Toronto, Toronto; Division of Rheumatology, Western University of Canada, London; Lynde Dermatology, Markham, Ontario; Faculty of Medicine, Memorial University of Newfoundland, St. John’s, Newfoundland, Canada. AbbVie sponsored a meeting on the management of comorbidities, held in Toronto, Ontario, Canada, on May 31 to June 1, 2013. This publication summarizes the results of the Canadian Dermatology-Rheumatology (DR) Co-morbidity Initiative systematic literature searches (MEDLINE, EMBASE, Cochrane Library, 2010–2012 American College of Rheumatology, European League Against Rheumatism, American Academy of Dermatology, European Academy of Dermatology and Venereology abstracts) and consensus-based recommendations from that meeting. AbbVie provided funding to Pinnacle Marketing and Education Inc. to manage the Canadian DR Co-morbidity Initiative that led to this paper. AbbVie paid consultancy fees to BH, JP, LB, SK, RB, WG, JD, CL, and JK for their participation in the Canadian DR Co-morbidity Initiative. AbbVie paid Leading Edge for editorial support. C. Roubille, MD, Rheumatology Research Fellow, University of Montreal Hospital Research Center (Centre de Recherche du CHUM), Notre-Dame Hospital; V. Richer, MD, Dermatology Resident, Department of Medicine, Dermatology Service, St-Luc Hospital; T. Starnino, MD, Rheumatology Resident, Sacré-Coeur Hospital of Montreal, University of Montreal; C. McCourt, MB, BCh, Clinical Fellow in Immunodermatology, Department of Dermatology and Skin Science, University of British Columbia; A. McFarlane, MD, Internal Medicine Resident, Division of Rheumatology, University of Alberta; P. Fleming, MD, Dermatology Resident, Division of Dermatology, University of Toronto; S. Siu, MD, Internal Medicine Resident, Division of Rheumatology, Western University of Canada; J. Kraft, MD, Dermatologist; C. Lynde, MD, Dermatologist, Lynde Dermatology; J. Pope, MD, Professor of Rheumatology, Division of Rheumatology, Western University of Canada; W. Gulliver, MD, Professor of Medicine, Faculty of Medicine, Memorial University of Newfoundland; S. Keeling, MD, Associate Professor of Rheumatology, Division of Rheumatology, University of Alberta; J. Dutz, MD, Professor of Dermatology, Department of Dermatology and Skin Science, University of British Columbia; L. Bessette, MD, Associate Professor of Medicine, Centre de Recherche du CHU de Québec, Department of Medicine, Laval University; R. Bissonnette, MD, Medical Director, Innovaderm Research; B. Haraoui, MD, Head of Clinical Research Unit, Institut de Rhumatologie de Montréal. Address correspondence to Dr. B. Haraoui, Institut de Rhumatologie de Montreal, 1551 Ontario St. East, Montreal, Quebec H2L 1S6, Canada. E-mail: boulos.haraoui@ssss.gouv.qc.ca. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication May 4, 2015.
Alexandra McFarlane
From the University of Montreal Hospital Research Center (Centre de Recherche du CHUM), Notre-Dame Hospital; Department of Medicine, Dermatology Service, St-Luc Hospital; Sacré-Coeur Hospital of Montreal, University of Montreal; Innovaderm Research; Institut de Rhumatologie de Montréal, Montreal; Centre de Recherche du CHU de Québec, Department of Medicine, Laval University, Quebec City, Quebec; Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia; Division of Rheumatology, University of Alberta, Edmonton, Alberta; Division of Dermatology, University of Toronto, Toronto; Division of Rheumatology, Western University of Canada, London; Lynde Dermatology, Markham, Ontario; Faculty of Medicine, Memorial University of Newfoundland, St. John’s, Newfoundland, Canada. AbbVie sponsored a meeting on the management of comorbidities, held in Toronto, Ontario, Canada, on May 31 to June 1, 2013. This publication summarizes the results of the Canadian Dermatology-Rheumatology (DR) Co-morbidity Initiative systematic literature searches (MEDLINE, EMBASE, Cochrane Library, 2010–2012 American College of Rheumatology, European League Against Rheumatism, American Academy of Dermatology, European Academy of Dermatology and Venereology abstracts) and consensus-based recommendations from that meeting. AbbVie provided funding to Pinnacle Marketing and Education Inc. to manage the Canadian DR Co-morbidity Initiative that led to this paper. AbbVie paid consultancy fees to BH, JP, LB, SK, RB, WG, JD, CL, and JK for their participation in the Canadian DR Co-morbidity Initiative. AbbVie paid Leading Edge for editorial support. C. Roubille, MD, Rheumatology Research Fellow, University of Montreal Hospital Research Center (Centre de Recherche du CHUM), Notre-Dame Hospital; V. Richer, MD, Dermatology Resident, Department of Medicine, Dermatology Service, St-Luc Hospital; T. Starnino, MD, Rheumatology Resident, Sacré-Coeur Hospital of Montreal, University of Montreal; C. McCourt, MB, BCh, Clinical Fellow in Immunodermatology, Department of Dermatology and Skin Science, University of British Columbia; A. McFarlane, MD, Internal Medicine Resident, Division of Rheumatology, University of Alberta; P. Fleming, MD, Dermatology Resident, Division of Dermatology, University of Toronto; S. Siu, MD, Internal Medicine Resident, Division of Rheumatology, Western University of Canada; J. Kraft, MD, Dermatologist; C. Lynde, MD, Dermatologist, Lynde Dermatology; J. Pope, MD, Professor of Rheumatology, Division of Rheumatology, Western University of Canada; W. Gulliver, MD, Professor of Medicine, Faculty of Medicine, Memorial University of Newfoundland; S. Keeling, MD, Associate Professor of Rheumatology, Division of Rheumatology, University of Alberta; J. Dutz, MD, Professor of Dermatology, Department of Dermatology and Skin Science, University of British Columbia; L. Bessette, MD, Associate Professor of Medicine, Centre de Recherche du CHU de Québec, Department of Medicine, Laval University; R. Bissonnette, MD, Medical Director, Innovaderm Research; B. Haraoui, MD, Head of Clinical Research Unit, Institut de Rhumatologie de Montréal. Address correspondence to Dr. B. Haraoui, Institut de Rhumatologie de Montreal, 1551 Ontario St. East, Montreal, Quebec H2L 1S6, Canada. E-mail: boulos.haraoui@ssss.gouv.qc.ca. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication May 4, 2015.
Patrick Fleming
From the University of Montreal Hospital Research Center (Centre de Recherche du CHUM), Notre-Dame Hospital; Department of Medicine, Dermatology Service, St-Luc Hospital; Sacré-Coeur Hospital of Montreal, University of Montreal; Innovaderm Research; Institut de Rhumatologie de Montréal, Montreal; Centre de Recherche du CHU de Québec, Department of Medicine, Laval University, Quebec City, Quebec; Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia; Division of Rheumatology, University of Alberta, Edmonton, Alberta; Division of Dermatology, University of Toronto, Toronto; Division of Rheumatology, Western University of Canada, London; Lynde Dermatology, Markham, Ontario; Faculty of Medicine, Memorial University of Newfoundland, St. John’s, Newfoundland, Canada. AbbVie sponsored a meeting on the management of comorbidities, held in Toronto, Ontario, Canada, on May 31 to June 1, 2013. This publication summarizes the results of the Canadian Dermatology-Rheumatology (DR) Co-morbidity Initiative systematic literature searches (MEDLINE, EMBASE, Cochrane Library, 2010–2012 American College of Rheumatology, European League Against Rheumatism, American Academy of Dermatology, European Academy of Dermatology and Venereology abstracts) and consensus-based recommendations from that meeting. AbbVie provided funding to Pinnacle Marketing and Education Inc. to manage the Canadian DR Co-morbidity Initiative that led to this paper. AbbVie paid consultancy fees to BH, JP, LB, SK, RB, WG, JD, CL, and JK for their participation in the Canadian DR Co-morbidity Initiative. AbbVie paid Leading Edge for editorial support. C. Roubille, MD, Rheumatology Research Fellow, University of Montreal Hospital Research Center (Centre de Recherche du CHUM), Notre-Dame Hospital; V. Richer, MD, Dermatology Resident, Department of Medicine, Dermatology Service, St-Luc Hospital; T. Starnino, MD, Rheumatology Resident, Sacré-Coeur Hospital of Montreal, University of Montreal; C. McCourt, MB, BCh, Clinical Fellow in Immunodermatology, Department of Dermatology and Skin Science, University of British Columbia; A. McFarlane, MD, Internal Medicine Resident, Division of Rheumatology, University of Alberta; P. Fleming, MD, Dermatology Resident, Division of Dermatology, University of Toronto; S. Siu, MD, Internal Medicine Resident, Division of Rheumatology, Western University of Canada; J. Kraft, MD, Dermatologist; C. Lynde, MD, Dermatologist, Lynde Dermatology; J. Pope, MD, Professor of Rheumatology, Division of Rheumatology, Western University of Canada; W. Gulliver, MD, Professor of Medicine, Faculty of Medicine, Memorial University of Newfoundland; S. Keeling, MD, Associate Professor of Rheumatology, Division of Rheumatology, University of Alberta; J. Dutz, MD, Professor of Dermatology, Department of Dermatology and Skin Science, University of British Columbia; L. Bessette, MD, Associate Professor of Medicine, Centre de Recherche du CHU de Québec, Department of Medicine, Laval University; R. Bissonnette, MD, Medical Director, Innovaderm Research; B. Haraoui, MD, Head of Clinical Research Unit, Institut de Rhumatologie de Montréal. Address correspondence to Dr. B. Haraoui, Institut de Rhumatologie de Montreal, 1551 Ontario St. East, Montreal, Quebec H2L 1S6, Canada. E-mail: boulos.haraoui@ssss.gouv.qc.ca. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication May 4, 2015.
Stephanie Siu
From the University of Montreal Hospital Research Center (Centre de Recherche du CHUM), Notre-Dame Hospital; Department of Medicine, Dermatology Service, St-Luc Hospital; Sacré-Coeur Hospital of Montreal, University of Montreal; Innovaderm Research; Institut de Rhumatologie de Montréal, Montreal; Centre de Recherche du CHU de Québec, Department of Medicine, Laval University, Quebec City, Quebec; Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia; Division of Rheumatology, University of Alberta, Edmonton, Alberta; Division of Dermatology, University of Toronto, Toronto; Division of Rheumatology, Western University of Canada, London; Lynde Dermatology, Markham, Ontario; Faculty of Medicine, Memorial University of Newfoundland, St. John’s, Newfoundland, Canada. AbbVie sponsored a meeting on the management of comorbidities, held in Toronto, Ontario, Canada, on May 31 to June 1, 2013. This publication summarizes the results of the Canadian Dermatology-Rheumatology (DR) Co-morbidity Initiative systematic literature searches (MEDLINE, EMBASE, Cochrane Library, 2010–2012 American College of Rheumatology, European League Against Rheumatism, American Academy of Dermatology, European Academy of Dermatology and Venereology abstracts) and consensus-based recommendations from that meeting. AbbVie provided funding to Pinnacle Marketing and Education Inc. to manage the Canadian DR Co-morbidity Initiative that led to this paper. AbbVie paid consultancy fees to BH, JP, LB, SK, RB, WG, JD, CL, and JK for their participation in the Canadian DR Co-morbidity Initiative. AbbVie paid Leading Edge for editorial support. C. Roubille, MD, Rheumatology Research Fellow, University of Montreal Hospital Research Center (Centre de Recherche du CHUM), Notre-Dame Hospital; V. Richer, MD, Dermatology Resident, Department of Medicine, Dermatology Service, St-Luc Hospital; T. Starnino, MD, Rheumatology Resident, Sacré-Coeur Hospital of Montreal, University of Montreal; C. McCourt, MB, BCh, Clinical Fellow in Immunodermatology, Department of Dermatology and Skin Science, University of British Columbia; A. McFarlane, MD, Internal Medicine Resident, Division of Rheumatology, University of Alberta; P. Fleming, MD, Dermatology Resident, Division of Dermatology, University of Toronto; S. Siu, MD, Internal Medicine Resident, Division of Rheumatology, Western University of Canada; J. Kraft, MD, Dermatologist; C. Lynde, MD, Dermatologist, Lynde Dermatology; J. Pope, MD, Professor of Rheumatology, Division of Rheumatology, Western University of Canada; W. Gulliver, MD, Professor of Medicine, Faculty of Medicine, Memorial University of Newfoundland; S. Keeling, MD, Associate Professor of Rheumatology, Division of Rheumatology, University of Alberta; J. Dutz, MD, Professor of Dermatology, Department of Dermatology and Skin Science, University of British Columbia; L. Bessette, MD, Associate Professor of Medicine, Centre de Recherche du CHU de Québec, Department of Medicine, Laval University; R. Bissonnette, MD, Medical Director, Innovaderm Research; B. Haraoui, MD, Head of Clinical Research Unit, Institut de Rhumatologie de Montréal. Address correspondence to Dr. B. Haraoui, Institut de Rhumatologie de Montreal, 1551 Ontario St. East, Montreal, Quebec H2L 1S6, Canada. E-mail: boulos.haraoui@ssss.gouv.qc.ca. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication May 4, 2015.
John Kraft
From the University of Montreal Hospital Research Center (Centre de Recherche du CHUM), Notre-Dame Hospital; Department of Medicine, Dermatology Service, St-Luc Hospital; Sacré-Coeur Hospital of Montreal, University of Montreal; Innovaderm Research; Institut de Rhumatologie de Montréal, Montreal; Centre de Recherche du CHU de Québec, Department of Medicine, Laval University, Quebec City, Quebec; Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia; Division of Rheumatology, University of Alberta, Edmonton, Alberta; Division of Dermatology, University of Toronto, Toronto; Division of Rheumatology, Western University of Canada, London; Lynde Dermatology, Markham, Ontario; Faculty of Medicine, Memorial University of Newfoundland, St. John’s, Newfoundland, Canada. AbbVie sponsored a meeting on the management of comorbidities, held in Toronto, Ontario, Canada, on May 31 to June 1, 2013. This publication summarizes the results of the Canadian Dermatology-Rheumatology (DR) Co-morbidity Initiative systematic literature searches (MEDLINE, EMBASE, Cochrane Library, 2010–2012 American College of Rheumatology, European League Against Rheumatism, American Academy of Dermatology, European Academy of Dermatology and Venereology abstracts) and consensus-based recommendations from that meeting. AbbVie provided funding to Pinnacle Marketing and Education Inc. to manage the Canadian DR Co-morbidity Initiative that led to this paper. AbbVie paid consultancy fees to BH, JP, LB, SK, RB, WG, JD, CL, and JK for their participation in the Canadian DR Co-morbidity Initiative. AbbVie paid Leading Edge for editorial support. C. Roubille, MD, Rheumatology Research Fellow, University of Montreal Hospital Research Center (Centre de Recherche du CHUM), Notre-Dame Hospital; V. Richer, MD, Dermatology Resident, Department of Medicine, Dermatology Service, St-Luc Hospital; T. Starnino, MD, Rheumatology Resident, Sacré-Coeur Hospital of Montreal, University of Montreal; C. McCourt, MB, BCh, Clinical Fellow in Immunodermatology, Department of Dermatology and Skin Science, University of British Columbia; A. McFarlane, MD, Internal Medicine Resident, Division of Rheumatology, University of Alberta; P. Fleming, MD, Dermatology Resident, Division of Dermatology, University of Toronto; S. Siu, MD, Internal Medicine Resident, Division of Rheumatology, Western University of Canada; J. Kraft, MD, Dermatologist; C. Lynde, MD, Dermatologist, Lynde Dermatology; J. Pope, MD, Professor of Rheumatology, Division of Rheumatology, Western University of Canada; W. Gulliver, MD, Professor of Medicine, Faculty of Medicine, Memorial University of Newfoundland; S. Keeling, MD, Associate Professor of Rheumatology, Division of Rheumatology, University of Alberta; J. Dutz, MD, Professor of Dermatology, Department of Dermatology and Skin Science, University of British Columbia; L. Bessette, MD, Associate Professor of Medicine, Centre de Recherche du CHU de Québec, Department of Medicine, Laval University; R. Bissonnette, MD, Medical Director, Innovaderm Research; B. Haraoui, MD, Head of Clinical Research Unit, Institut de Rhumatologie de Montréal. Address correspondence to Dr. B. Haraoui, Institut de Rhumatologie de Montreal, 1551 Ontario St. East, Montreal, Quebec H2L 1S6, Canada. E-mail: boulos.haraoui@ssss.gouv.qc.ca. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication May 4, 2015.
Charles Lynde
From the University of Montreal Hospital Research Center (Centre de Recherche du CHUM), Notre-Dame Hospital; Department of Medicine, Dermatology Service, St-Luc Hospital; Sacré-Coeur Hospital of Montreal, University of Montreal; Innovaderm Research; Institut de Rhumatologie de Montréal, Montreal; Centre de Recherche du CHU de Québec, Department of Medicine, Laval University, Quebec City, Quebec; Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia; Division of Rheumatology, University of Alberta, Edmonton, Alberta; Division of Dermatology, University of Toronto, Toronto; Division of Rheumatology, Western University of Canada, London; Lynde Dermatology, Markham, Ontario; Faculty of Medicine, Memorial University of Newfoundland, St. John’s, Newfoundland, Canada. AbbVie sponsored a meeting on the management of comorbidities, held in Toronto, Ontario, Canada, on May 31 to June 1, 2013. This publication summarizes the results of the Canadian Dermatology-Rheumatology (DR) Co-morbidity Initiative systematic literature searches (MEDLINE, EMBASE, Cochrane Library, 2010–2012 American College of Rheumatology, European League Against Rheumatism, American Academy of Dermatology, European Academy of Dermatology and Venereology abstracts) and consensus-based recommendations from that meeting. AbbVie provided funding to Pinnacle Marketing and Education Inc. to manage the Canadian DR Co-morbidity Initiative that led to this paper. AbbVie paid consultancy fees to BH, JP, LB, SK, RB, WG, JD, CL, and JK for their participation in the Canadian DR Co-morbidity Initiative. AbbVie paid Leading Edge for editorial support. C. Roubille, MD, Rheumatology Research Fellow, University of Montreal Hospital Research Center (Centre de Recherche du CHUM), Notre-Dame Hospital; V. Richer, MD, Dermatology Resident, Department of Medicine, Dermatology Service, St-Luc Hospital; T. Starnino, MD, Rheumatology Resident, Sacré-Coeur Hospital of Montreal, University of Montreal; C. McCourt, MB, BCh, Clinical Fellow in Immunodermatology, Department of Dermatology and Skin Science, University of British Columbia; A. McFarlane, MD, Internal Medicine Resident, Division of Rheumatology, University of Alberta; P. Fleming, MD, Dermatology Resident, Division of Dermatology, University of Toronto; S. Siu, MD, Internal Medicine Resident, Division of Rheumatology, Western University of Canada; J. Kraft, MD, Dermatologist; C. Lynde, MD, Dermatologist, Lynde Dermatology; J. Pope, MD, Professor of Rheumatology, Division of Rheumatology, Western University of Canada; W. Gulliver, MD, Professor of Medicine, Faculty of Medicine, Memorial University of Newfoundland; S. Keeling, MD, Associate Professor of Rheumatology, Division of Rheumatology, University of Alberta; J. Dutz, MD, Professor of Dermatology, Department of Dermatology and Skin Science, University of British Columbia; L. Bessette, MD, Associate Professor of Medicine, Centre de Recherche du CHU de Québec, Department of Medicine, Laval University; R. Bissonnette, MD, Medical Director, Innovaderm Research; B. Haraoui, MD, Head of Clinical Research Unit, Institut de Rhumatologie de Montréal. Address correspondence to Dr. B. Haraoui, Institut de Rhumatologie de Montreal, 1551 Ontario St. East, Montreal, Quebec H2L 1S6, Canada. E-mail: boulos.haraoui@ssss.gouv.qc.ca. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication May 4, 2015.
Janet Pope
From the University of Montreal Hospital Research Center (Centre de Recherche du CHUM), Notre-Dame Hospital; Department of Medicine, Dermatology Service, St-Luc Hospital; Sacré-Coeur Hospital of Montreal, University of Montreal; Innovaderm Research; Institut de Rhumatologie de Montréal, Montreal; Centre de Recherche du CHU de Québec, Department of Medicine, Laval University, Quebec City, Quebec; Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia; Division of Rheumatology, University of Alberta, Edmonton, Alberta; Division of Dermatology, University of Toronto, Toronto; Division of Rheumatology, Western University of Canada, London; Lynde Dermatology, Markham, Ontario; Faculty of Medicine, Memorial University of Newfoundland, St. John’s, Newfoundland, Canada. AbbVie sponsored a meeting on the management of comorbidities, held in Toronto, Ontario, Canada, on May 31 to June 1, 2013. This publication summarizes the results of the Canadian Dermatology-Rheumatology (DR) Co-morbidity Initiative systematic literature searches (MEDLINE, EMBASE, Cochrane Library, 2010–2012 American College of Rheumatology, European League Against Rheumatism, American Academy of Dermatology, European Academy of Dermatology and Venereology abstracts) and consensus-based recommendations from that meeting. AbbVie provided funding to Pinnacle Marketing and Education Inc. to manage the Canadian DR Co-morbidity Initiative that led to this paper. AbbVie paid consultancy fees to BH, JP, LB, SK, RB, WG, JD, CL, and JK for their participation in the Canadian DR Co-morbidity Initiative. AbbVie paid Leading Edge for editorial support. C. Roubille, MD, Rheumatology Research Fellow, University of Montreal Hospital Research Center (Centre de Recherche du CHUM), Notre-Dame Hospital; V. Richer, MD, Dermatology Resident, Department of Medicine, Dermatology Service, St-Luc Hospital; T. Starnino, MD, Rheumatology Resident, Sacré-Coeur Hospital of Montreal, University of Montreal; C. McCourt, MB, BCh, Clinical Fellow in Immunodermatology, Department of Dermatology and Skin Science, University of British Columbia; A. McFarlane, MD, Internal Medicine Resident, Division of Rheumatology, University of Alberta; P. Fleming, MD, Dermatology Resident, Division of Dermatology, University of Toronto; S. Siu, MD, Internal Medicine Resident, Division of Rheumatology, Western University of Canada; J. Kraft, MD, Dermatologist; C. Lynde, MD, Dermatologist, Lynde Dermatology; J. Pope, MD, Professor of Rheumatology, Division of Rheumatology, Western University of Canada; W. Gulliver, MD, Professor of Medicine, Faculty of Medicine, Memorial University of Newfoundland; S. Keeling, MD, Associate Professor of Rheumatology, Division of Rheumatology, University of Alberta; J. Dutz, MD, Professor of Dermatology, Department of Dermatology and Skin Science, University of British Columbia; L. Bessette, MD, Associate Professor of Medicine, Centre de Recherche du CHU de Québec, Department of Medicine, Laval University; R. Bissonnette, MD, Medical Director, Innovaderm Research; B. Haraoui, MD, Head of Clinical Research Unit, Institut de Rhumatologie de Montréal. Address correspondence to Dr. B. Haraoui, Institut de Rhumatologie de Montreal, 1551 Ontario St. East, Montreal, Quebec H2L 1S6, Canada. E-mail: boulos.haraoui@ssss.gouv.qc.ca. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication May 4, 2015.
Wayne Gulliver
From the University of Montreal Hospital Research Center (Centre de Recherche du CHUM), Notre-Dame Hospital; Department of Medicine, Dermatology Service, St-Luc Hospital; Sacré-Coeur Hospital of Montreal, University of Montreal; Innovaderm Research; Institut de Rhumatologie de Montréal, Montreal; Centre de Recherche du CHU de Québec, Department of Medicine, Laval University, Quebec City, Quebec; Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia; Division of Rheumatology, University of Alberta, Edmonton, Alberta; Division of Dermatology, University of Toronto, Toronto; Division of Rheumatology, Western University of Canada, London; Lynde Dermatology, Markham, Ontario; Faculty of Medicine, Memorial University of Newfoundland, St. John’s, Newfoundland, Canada. AbbVie sponsored a meeting on the management of comorbidities, held in Toronto, Ontario, Canada, on May 31 to June 1, 2013. This publication summarizes the results of the Canadian Dermatology-Rheumatology (DR) Co-morbidity Initiative systematic literature searches (MEDLINE, EMBASE, Cochrane Library, 2010–2012 American College of Rheumatology, European League Against Rheumatism, American Academy of Dermatology, European Academy of Dermatology and Venereology abstracts) and consensus-based recommendations from that meeting. AbbVie provided funding to Pinnacle Marketing and Education Inc. to manage the Canadian DR Co-morbidity Initiative that led to this paper. AbbVie paid consultancy fees to BH, JP, LB, SK, RB, WG, JD, CL, and JK for their participation in the Canadian DR Co-morbidity Initiative. AbbVie paid Leading Edge for editorial support. C. Roubille, MD, Rheumatology Research Fellow, University of Montreal Hospital Research Center (Centre de Recherche du CHUM), Notre-Dame Hospital; V. Richer, MD, Dermatology Resident, Department of Medicine, Dermatology Service, St-Luc Hospital; T. Starnino, MD, Rheumatology Resident, Sacré-Coeur Hospital of Montreal, University of Montreal; C. McCourt, MB, BCh, Clinical Fellow in Immunodermatology, Department of Dermatology and Skin Science, University of British Columbia; A. McFarlane, MD, Internal Medicine Resident, Division of Rheumatology, University of Alberta; P. Fleming, MD, Dermatology Resident, Division of Dermatology, University of Toronto; S. Siu, MD, Internal Medicine Resident, Division of Rheumatology, Western University of Canada; J. Kraft, MD, Dermatologist; C. Lynde, MD, Dermatologist, Lynde Dermatology; J. Pope, MD, Professor of Rheumatology, Division of Rheumatology, Western University of Canada; W. Gulliver, MD, Professor of Medicine, Faculty of Medicine, Memorial University of Newfoundland; S. Keeling, MD, Associate Professor of Rheumatology, Division of Rheumatology, University of Alberta; J. Dutz, MD, Professor of Dermatology, Department of Dermatology and Skin Science, University of British Columbia; L. Bessette, MD, Associate Professor of Medicine, Centre de Recherche du CHU de Québec, Department of Medicine, Laval University; R. Bissonnette, MD, Medical Director, Innovaderm Research; B. Haraoui, MD, Head of Clinical Research Unit, Institut de Rhumatologie de Montréal. Address correspondence to Dr. B. Haraoui, Institut de Rhumatologie de Montreal, 1551 Ontario St. East, Montreal, Quebec H2L 1S6, Canada. E-mail: boulos.haraoui@ssss.gouv.qc.ca. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication May 4, 2015.
Stephanie Keeling
From the University of Montreal Hospital Research Center (Centre de Recherche du CHUM), Notre-Dame Hospital; Department of Medicine, Dermatology Service, St-Luc Hospital; Sacré-Coeur Hospital of Montreal, University of Montreal; Innovaderm Research; Institut de Rhumatologie de Montréal, Montreal; Centre de Recherche du CHU de Québec, Department of Medicine, Laval University, Quebec City, Quebec; Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia; Division of Rheumatology, University of Alberta, Edmonton, Alberta; Division of Dermatology, University of Toronto, Toronto; Division of Rheumatology, Western University of Canada, London; Lynde Dermatology, Markham, Ontario; Faculty of Medicine, Memorial University of Newfoundland, St. John’s, Newfoundland, Canada. AbbVie sponsored a meeting on the management of comorbidities, held in Toronto, Ontario, Canada, on May 31 to June 1, 2013. This publication summarizes the results of the Canadian Dermatology-Rheumatology (DR) Co-morbidity Initiative systematic literature searches (MEDLINE, EMBASE, Cochrane Library, 2010–2012 American College of Rheumatology, European League Against Rheumatism, American Academy of Dermatology, European Academy of Dermatology and Venereology abstracts) and consensus-based recommendations from that meeting. AbbVie provided funding to Pinnacle Marketing and Education Inc. to manage the Canadian DR Co-morbidity Initiative that led to this paper. AbbVie paid consultancy fees to BH, JP, LB, SK, RB, WG, JD, CL, and JK for their participation in the Canadian DR Co-morbidity Initiative. AbbVie paid Leading Edge for editorial support. C. Roubille, MD, Rheumatology Research Fellow, University of Montreal Hospital Research Center (Centre de Recherche du CHUM), Notre-Dame Hospital; V. Richer, MD, Dermatology Resident, Department of Medicine, Dermatology Service, St-Luc Hospital; T. Starnino, MD, Rheumatology Resident, Sacré-Coeur Hospital of Montreal, University of Montreal; C. McCourt, MB, BCh, Clinical Fellow in Immunodermatology, Department of Dermatology and Skin Science, University of British Columbia; A. McFarlane, MD, Internal Medicine Resident, Division of Rheumatology, University of Alberta; P. Fleming, MD, Dermatology Resident, Division of Dermatology, University of Toronto; S. Siu, MD, Internal Medicine Resident, Division of Rheumatology, Western University of Canada; J. Kraft, MD, Dermatologist; C. Lynde, MD, Dermatologist, Lynde Dermatology; J. Pope, MD, Professor of Rheumatology, Division of Rheumatology, Western University of Canada; W. Gulliver, MD, Professor of Medicine, Faculty of Medicine, Memorial University of Newfoundland; S. Keeling, MD, Associate Professor of Rheumatology, Division of Rheumatology, University of Alberta; J. Dutz, MD, Professor of Dermatology, Department of Dermatology and Skin Science, University of British Columbia; L. Bessette, MD, Associate Professor of Medicine, Centre de Recherche du CHU de Québec, Department of Medicine, Laval University; R. Bissonnette, MD, Medical Director, Innovaderm Research; B. Haraoui, MD, Head of Clinical Research Unit, Institut de Rhumatologie de Montréal. Address correspondence to Dr. B. Haraoui, Institut de Rhumatologie de Montreal, 1551 Ontario St. East, Montreal, Quebec H2L 1S6, Canada. E-mail: boulos.haraoui@ssss.gouv.qc.ca. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication May 4, 2015.
Jan Dutz
From the University of Montreal Hospital Research Center (Centre de Recherche du CHUM), Notre-Dame Hospital; Department of Medicine, Dermatology Service, St-Luc Hospital; Sacré-Coeur Hospital of Montreal, University of Montreal; Innovaderm Research; Institut de Rhumatologie de Montréal, Montreal; Centre de Recherche du CHU de Québec, Department of Medicine, Laval University, Quebec City, Quebec; Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia; Division of Rheumatology, University of Alberta, Edmonton, Alberta; Division of Dermatology, University of Toronto, Toronto; Division of Rheumatology, Western University of Canada, London; Lynde Dermatology, Markham, Ontario; Faculty of Medicine, Memorial University of Newfoundland, St. John’s, Newfoundland, Canada. AbbVie sponsored a meeting on the management of comorbidities, held in Toronto, Ontario, Canada, on May 31 to June 1, 2013. This publication summarizes the results of the Canadian Dermatology-Rheumatology (DR) Co-morbidity Initiative systematic literature searches (MEDLINE, EMBASE, Cochrane Library, 2010–2012 American College of Rheumatology, European League Against Rheumatism, American Academy of Dermatology, European Academy of Dermatology and Venereology abstracts) and consensus-based recommendations from that meeting. AbbVie provided funding to Pinnacle Marketing and Education Inc. to manage the Canadian DR Co-morbidity Initiative that led to this paper. AbbVie paid consultancy fees to BH, JP, LB, SK, RB, WG, JD, CL, and JK for their participation in the Canadian DR Co-morbidity Initiative. AbbVie paid Leading Edge for editorial support. C. Roubille, MD, Rheumatology Research Fellow, University of Montreal Hospital Research Center (Centre de Recherche du CHUM), Notre-Dame Hospital; V. Richer, MD, Dermatology Resident, Department of Medicine, Dermatology Service, St-Luc Hospital; T. Starnino, MD, Rheumatology Resident, Sacré-Coeur Hospital of Montreal, University of Montreal; C. McCourt, MB, BCh, Clinical Fellow in Immunodermatology, Department of Dermatology and Skin Science, University of British Columbia; A. McFarlane, MD, Internal Medicine Resident, Division of Rheumatology, University of Alberta; P. Fleming, MD, Dermatology Resident, Division of Dermatology, University of Toronto; S. Siu, MD, Internal Medicine Resident, Division of Rheumatology, Western University of Canada; J. Kraft, MD, Dermatologist; C. Lynde, MD, Dermatologist, Lynde Dermatology; J. Pope, MD, Professor of Rheumatology, Division of Rheumatology, Western University of Canada; W. Gulliver, MD, Professor of Medicine, Faculty of Medicine, Memorial University of Newfoundland; S. Keeling, MD, Associate Professor of Rheumatology, Division of Rheumatology, University of Alberta; J. Dutz, MD, Professor of Dermatology, Department of Dermatology and Skin Science, University of British Columbia; L. Bessette, MD, Associate Professor of Medicine, Centre de Recherche du CHU de Québec, Department of Medicine, Laval University; R. Bissonnette, MD, Medical Director, Innovaderm Research; B. Haraoui, MD, Head of Clinical Research Unit, Institut de Rhumatologie de Montréal. Address correspondence to Dr. B. Haraoui, Institut de Rhumatologie de Montreal, 1551 Ontario St. East, Montreal, Quebec H2L 1S6, Canada. E-mail: boulos.haraoui@ssss.gouv.qc.ca. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication May 4, 2015.
Louis Bessette
From the University of Montreal Hospital Research Center (Centre de Recherche du CHUM), Notre-Dame Hospital; Department of Medicine, Dermatology Service, St-Luc Hospital; Sacré-Coeur Hospital of Montreal, University of Montreal; Innovaderm Research; Institut de Rhumatologie de Montréal, Montreal; Centre de Recherche du CHU de Québec, Department of Medicine, Laval University, Quebec City, Quebec; Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia; Division of Rheumatology, University of Alberta, Edmonton, Alberta; Division of Dermatology, University of Toronto, Toronto; Division of Rheumatology, Western University of Canada, London; Lynde Dermatology, Markham, Ontario; Faculty of Medicine, Memorial University of Newfoundland, St. John’s, Newfoundland, Canada. AbbVie sponsored a meeting on the management of comorbidities, held in Toronto, Ontario, Canada, on May 31 to June 1, 2013. This publication summarizes the results of the Canadian Dermatology-Rheumatology (DR) Co-morbidity Initiative systematic literature searches (MEDLINE, EMBASE, Cochrane Library, 2010–2012 American College of Rheumatology, European League Against Rheumatism, American Academy of Dermatology, European Academy of Dermatology and Venereology abstracts) and consensus-based recommendations from that meeting. AbbVie provided funding to Pinnacle Marketing and Education Inc. to manage the Canadian DR Co-morbidity Initiative that led to this paper. AbbVie paid consultancy fees to BH, JP, LB, SK, RB, WG, JD, CL, and JK for their participation in the Canadian DR Co-morbidity Initiative. AbbVie paid Leading Edge for editorial support. C. Roubille, MD, Rheumatology Research Fellow, University of Montreal Hospital Research Center (Centre de Recherche du CHUM), Notre-Dame Hospital; V. Richer, MD, Dermatology Resident, Department of Medicine, Dermatology Service, St-Luc Hospital; T. Starnino, MD, Rheumatology Resident, Sacré-Coeur Hospital of Montreal, University of Montreal; C. McCourt, MB, BCh, Clinical Fellow in Immunodermatology, Department of Dermatology and Skin Science, University of British Columbia; A. McFarlane, MD, Internal Medicine Resident, Division of Rheumatology, University of Alberta; P. Fleming, MD, Dermatology Resident, Division of Dermatology, University of Toronto; S. Siu, MD, Internal Medicine Resident, Division of Rheumatology, Western University of Canada; J. Kraft, MD, Dermatologist; C. Lynde, MD, Dermatologist, Lynde Dermatology; J. Pope, MD, Professor of Rheumatology, Division of Rheumatology, Western University of Canada; W. Gulliver, MD, Professor of Medicine, Faculty of Medicine, Memorial University of Newfoundland; S. Keeling, MD, Associate Professor of Rheumatology, Division of Rheumatology, University of Alberta; J. Dutz, MD, Professor of Dermatology, Department of Dermatology and Skin Science, University of British Columbia; L. Bessette, MD, Associate Professor of Medicine, Centre de Recherche du CHU de Québec, Department of Medicine, Laval University; R. Bissonnette, MD, Medical Director, Innovaderm Research; B. Haraoui, MD, Head of Clinical Research Unit, Institut de Rhumatologie de Montréal. Address correspondence to Dr. B. Haraoui, Institut de Rhumatologie de Montreal, 1551 Ontario St. East, Montreal, Quebec H2L 1S6, Canada. E-mail: boulos.haraoui@ssss.gouv.qc.ca. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication May 4, 2015.
Robert Bissonnette
From the University of Montreal Hospital Research Center (Centre de Recherche du CHUM), Notre-Dame Hospital; Department of Medicine, Dermatology Service, St-Luc Hospital; Sacré-Coeur Hospital of Montreal, University of Montreal; Innovaderm Research; Institut de Rhumatologie de Montréal, Montreal; Centre de Recherche du CHU de Québec, Department of Medicine, Laval University, Quebec City, Quebec; Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia; Division of Rheumatology, University of Alberta, Edmonton, Alberta; Division of Dermatology, University of Toronto, Toronto; Division of Rheumatology, Western University of Canada, London; Lynde Dermatology, Markham, Ontario; Faculty of Medicine, Memorial University of Newfoundland, St. John’s, Newfoundland, Canada. AbbVie sponsored a meeting on the management of comorbidities, held in Toronto, Ontario, Canada, on May 31 to June 1, 2013. This publication summarizes the results of the Canadian Dermatology-Rheumatology (DR) Co-morbidity Initiative systematic literature searches (MEDLINE, EMBASE, Cochrane Library, 2010–2012 American College of Rheumatology, European League Against Rheumatism, American Academy of Dermatology, European Academy of Dermatology and Venereology abstracts) and consensus-based recommendations from that meeting. AbbVie provided funding to Pinnacle Marketing and Education Inc. to manage the Canadian DR Co-morbidity Initiative that led to this paper. AbbVie paid consultancy fees to BH, JP, LB, SK, RB, WG, JD, CL, and JK for their participation in the Canadian DR Co-morbidity Initiative. AbbVie paid Leading Edge for editorial support. C. Roubille, MD, Rheumatology Research Fellow, University of Montreal Hospital Research Center (Centre de Recherche du CHUM), Notre-Dame Hospital; V. Richer, MD, Dermatology Resident, Department of Medicine, Dermatology Service, St-Luc Hospital; T. Starnino, MD, Rheumatology Resident, Sacré-Coeur Hospital of Montreal, University of Montreal; C. McCourt, MB, BCh, Clinical Fellow in Immunodermatology, Department of Dermatology and Skin Science, University of British Columbia; A. McFarlane, MD, Internal Medicine Resident, Division of Rheumatology, University of Alberta; P. Fleming, MD, Dermatology Resident, Division of Dermatology, University of Toronto; S. Siu, MD, Internal Medicine Resident, Division of Rheumatology, Western University of Canada; J. Kraft, MD, Dermatologist; C. Lynde, MD, Dermatologist, Lynde Dermatology; J. Pope, MD, Professor of Rheumatology, Division of Rheumatology, Western University of Canada; W. Gulliver, MD, Professor of Medicine, Faculty of Medicine, Memorial University of Newfoundland; S. Keeling, MD, Associate Professor of Rheumatology, Division of Rheumatology, University of Alberta; J. Dutz, MD, Professor of Dermatology, Department of Dermatology and Skin Science, University of British Columbia; L. Bessette, MD, Associate Professor of Medicine, Centre de Recherche du CHU de Québec, Department of Medicine, Laval University; R. Bissonnette, MD, Medical Director, Innovaderm Research; B. Haraoui, MD, Head of Clinical Research Unit, Institut de Rhumatologie de Montréal. Address correspondence to Dr. B. Haraoui, Institut de Rhumatologie de Montreal, 1551 Ontario St. East, Montreal, Quebec H2L 1S6, Canada. E-mail: boulos.haraoui@ssss.gouv.qc.ca. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication May 4, 2015.
Boulos Haraoui
From the University of Montreal Hospital Research Center (Centre de Recherche du CHUM), Notre-Dame Hospital; Department of Medicine, Dermatology Service, St-Luc Hospital; Sacré-Coeur Hospital of Montreal, University of Montreal; Innovaderm Research; Institut de Rhumatologie de Montréal, Montreal; Centre de Recherche du CHU de Québec, Department of Medicine, Laval University, Quebec City, Quebec; Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia; Division of Rheumatology, University of Alberta, Edmonton, Alberta; Division of Dermatology, University of Toronto, Toronto; Division of Rheumatology, Western University of Canada, London; Lynde Dermatology, Markham, Ontario; Faculty of Medicine, Memorial University of Newfoundland, St. John’s, Newfoundland, Canada. AbbVie sponsored a meeting on the management of comorbidities, held in Toronto, Ontario, Canada, on May 31 to June 1, 2013. This publication summarizes the results of the Canadian Dermatology-Rheumatology (DR) Co-morbidity Initiative systematic literature searches (MEDLINE, EMBASE, Cochrane Library, 2010–2012 American College of Rheumatology, European League Against Rheumatism, American Academy of Dermatology, European Academy of Dermatology and Venereology abstracts) and consensus-based recommendations from that meeting. AbbVie provided funding to Pinnacle Marketing and Education Inc. to manage the Canadian DR Co-morbidity Initiative that led to this paper. AbbVie paid consultancy fees to BH, JP, LB, SK, RB, WG, JD, CL, and JK for their participation in the Canadian DR Co-morbidity Initiative. AbbVie paid Leading Edge for editorial support. C. Roubille, MD, Rheumatology Research Fellow, University of Montreal Hospital Research Center (Centre de Recherche du CHUM), Notre-Dame Hospital; V. Richer, MD, Dermatology Resident, Department of Medicine, Dermatology Service, St-Luc Hospital; T. Starnino, MD, Rheumatology Resident, Sacré-Coeur Hospital of Montreal, University of Montreal; C. McCourt, MB, BCh, Clinical Fellow in Immunodermatology, Department of Dermatology and Skin Science, University of British Columbia; A. McFarlane, MD, Internal Medicine Resident, Division of Rheumatology, University of Alberta; P. Fleming, MD, Dermatology Resident, Division of Dermatology, University of Toronto; S. Siu, MD, Internal Medicine Resident, Division of Rheumatology, Western University of Canada; J. Kraft, MD, Dermatologist; C. Lynde, MD, Dermatologist, Lynde Dermatology; J. Pope, MD, Professor of Rheumatology, Division of Rheumatology, Western University of Canada; W. Gulliver, MD, Professor of Medicine, Faculty of Medicine, Memorial University of Newfoundland; S. Keeling, MD, Associate Professor of Rheumatology, Division of Rheumatology, University of Alberta; J. Dutz, MD, Professor of Dermatology, Department of Dermatology and Skin Science, University of British Columbia; L. Bessette, MD, Associate Professor of Medicine, Centre de Recherche du CHU de Québec, Department of Medicine, Laval University; R. Bissonnette, MD, Medical Director, Innovaderm Research; B. Haraoui, MD, Head of Clinical Research Unit, Institut de Rhumatologie de Montréal. Address correspondence to Dr. B. Haraoui, Institut de Rhumatologie de Montreal, 1551 Ontario St. East, Montreal, Quebec H2L 1S6, Canada. E-mail: boulos.haraoui@ssss.gouv.qc.ca. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication May 4, 2015.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Evidence-based Recommendations for the Management of Comorbidities in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Expert Opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative
Camille Roubille, Vincent Richer, Tara Starnino, Collette McCourt, Alexandra McFarlane, Patrick Fleming, Stephanie Siu, John Kraft, Charles Lynde, Janet Pope, Wayne Gulliver, Stephanie Keeling, Jan Dutz, Louis Bessette, Robert Bissonnette, Boulos Haraoui
The Journal of Rheumatology Jul 2015, jrheum.141112; DOI: 10.3899/jrheum.141112
Evidence-based Recommendations for the Management of Comorbidities in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Expert Opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative
Camille Roubille, Vincent Richer, Tara Starnino, Collette McCourt, Alexandra McFarlane, Patrick Fleming, Stephanie Siu, John Kraft, Charles Lynde, Janet Pope, Wayne Gulliver, Stephanie Keeling, Jan Dutz, Louis Bessette, Robert Bissonnette, Boulos Haraoui
The Journal of Rheumatology Jul 2015, jrheum.141112; DOI: 10.3899/jrheum.141112